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In the past decade, the number of autologous hematopoietic stem cell transplants (Auto HSCT) for older
patients with multiple myeloma (MM) has increased dramatically, as has the cost of transplantation. The cost-
effectiveness of this modality in patients over age 65 is unclear. Using the Surveillance, Epidemiology, and End
ResultseMedicare database to create a propensity-score matched sample of patients over age 65 between
2000 and 2007, we compared the survival and cost for those who received Auto HSCT to those who did not
undergo transplantation but survived at least 6 months after diagnosis, and we calculated an incremental
cost-effectiveness ratio (ICER). Two hundred seventy patients underwent transplantation. Median overall
survival from diagnosis in those who underwent transplantation was signiﬁcantly longer than in patients
who did not (58 months versus 37 months, P < .001). For patients living longer than 2 years, the median
monthly cost during the ﬁrst year was signiﬁcantly different, but the middle and last year of life costs were
similar. The median cost of the ﬁrst 100 days after transplantation was $60,000 (range, $37,000 to $85,000).
The resultant ICER was $72,852 per life-year gained. Survival after transplantation was comparable to that in
those who underwent transplantation patients under 65 years and signiﬁcantly longer than older patients
who did not undergo transplantation. With an ICER less than $100,000/life-year gained, Auto HSCT is cost-
effective when compared with nontransplantation care in the era of novel agents and should be consid-
ered, where clinically indicated, for patients over the age of 65.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Multiple myeloma (MM) is deﬁned by an increased clonal
plasma cell population and the presence of hypercalcemia,
renal dysfunction, anemia, or bone disease attributable to the
plasma cells [1]. Incidence increases with age; in the United
States, the median age at diagnosis is 69 years. In 2014,dgments on page 1827.
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ty for Blood and Marrow Transplantation.approximately 24,050 new cases were diagnosedwith 11,090
deaths, making it the second most common hematologic
malignancy [2]. Over the past 2 decades, survival for patients
with MM has increased as the result of several factors: the
use of novel agents, autologous stem cell transplantation
(Auto HSCT), and improved supportive care [3,4].
Induction chemotherapy followed by high-dose
melphalan with Auto HSCT is standard of care for the treat-
ment of MM in younger patients, with median overall sur-
vival (OS) prolonged by at least 12 months with the use of
Auto HSCT [5,6]. On the strength of these results, Auto HSCT
has been increasingly used in patients over the age of 65. For
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patients up to age 78 began in 2000. Since that time, there
has been a dramatic rise in the utilization of Auto HSCT;
between 2005 and 2011, almost 40% of Auto HSCT in the
United States were performed on patients over age 60, with
the leading indication being MM [7-9].
In the 2009 report from the Agency for Healthcare
Research and Quality, the most rapid increase in total hos-
pital costs between 2004 and 2007 was in HSCT (both
autologous and allogeneic) with $1.3 billion spent in 2007, an
increase of about 85% since 2004 [10]. This increase was
attributed not only to the increased cost of the procedure, but
also to an increase in the number of patients receiving the
modality. Although most published reports of cost have been
from single institutions with varied populations, treatment
regimens, and diseases [11], recent papers reporting large
claims data [12] and a decision analysis ﬁnding early Auto
HSCT cost-effective compared with late Auto HSCT [13] were
published. Studies focusing on the economics of trans-
plantation for MM are otherwise few, focus on younger pa-
tients, and mostly not from US centers [12-20]. In general,
these studies have concluded that although Auto HSCT has a
higher incremental cost than therapy without trans-
plantation, there is also greater incremental life-year (LY) or
quality-adjusted life year (QALY) beneﬁt [21].
As the survival and cost implications of the rise in Auto
HSCT are not well described in the elderly MM population
and are only likely to increase as the US population ages, we
used the Surveillance, Epidemiology, and End Results (SEER)-
Medicare database to examine the cost-effectiveness of un-
dergoing an Auto HSCT compared with conventional
chemotherapy alone for patients over the age of 65.
METHODS
Data Source
This study used data from the merged SEER-Medicare database. Patients
in the SEER registries (Appendix 1) were linked to their fee-for-service (FFS)
Medicare claims successfully in 93% of cases over age 65, representing
approximately 26% of the United States. SEER completeness of case ascer-
tainment is 98% with incident cases through December 31, 2007 and
Medicare claims through December 31, 2009 included in the most recent
linkage completed in 2012 [22,23]. The Patient Entitlement and Diagnosis
Summary (Medicare enrollment information), the Medicare Provider Anal-
ysis and Review (inpatient Medicare Part A claims), the National Claims
History ﬁle (provider Medicare Part B claims), Outpatient (institutional
Medicare Part B claims) ﬁles, Durable Medical Equipment ﬁles, Hospice ﬁles,
and Home Health ﬁles were used in this analysis. Patients were eligible for
our sample if they were enrolled in Parts A and B FFS Medicare for at least 1
year before diagnosis and for at least 1 year after diagnosis or until death.
Transplanted Patient Sample
Patients with MM as their ﬁrst cancer diagnosis were identiﬁed through
the SEER diagnosis code. As Medicare coverage of Auto HSCT for MM began
on October 1, 2000, we restricted our study to cases diagnosed after this
date. We used International Classiﬁcation of Disease 9 codes (41.00, 41.01,
41.04, 41.07, 41.09) or Healthcare Common Procedure Coding System
(38241) codes to identify patients who had an Auto HSCT after MM diag-
nosis. Cases were required to be greater than or equal to 66 years old at
diagnosis to allow for calculation of the comorbidity index, based on the
Charlson comorbidity index (CCI) [24] in the year before diagnosis. Patients
were designated as CCI 0 if they had no comorbidities and CCI 1þ if they
have a score of 1 or more. Comorbidity information was available for all
patients.
Nontransplanted Patient Sample
For the primary analysis, a matched cohort of MM patients not under-
going Auto HSCT was created from patients living at least 180 days from
diagnosis and not having any Auto HSCTespeciﬁc code after their diagnosis
to ensure that they would have lived long enough to complete a course of
induction therapy and to have been offered a transplantation. Using age,
gender, race, comorbidity, year of diagnosis, and SEER location, a propensityscore of the likelihood to undergo Auto HSCT was created and greedy
matching [25] was used to determine a 1:1 sample. A second model using
instrumental variables, which are selected to take into account both
observed and unobserved patient characteristics in both groups, as done by
Potosky et al. [26], served as a sensitivity analysis for our matched sample
and is reported elsewhere. A second sensitivity analysis was done, condi-
tioned on patients living to 12 months, to explore if the incremental cost-
effectiveness ration (ICER) changed with longer survival required for
inclusion.
Survival Outcomes
Date of death was determined from the SEER Patient Entitlement and
Diagnosis Summary File. We estimated survival for the ﬁrst 100 days, 1 year,
3 years, and 5 years after diagnosis using the Kaplan-Meier method [27],
stratiﬁed by whether a patient received a transplant. Patients were followed
for up to 9 years and the log-rank test was used to test for signiﬁcance in
median survival.
Cost
Costs were based on the services paid by Medicare, including claims for
inpatient and outpatient services, radiographic imaging, laboratory testing,
physician services, and pharmaceuticals delivered in the hospital or clinic.
Medicare Part D data was not available during our time frame and, thus, the
costs of outpatient prescriptions are not included in this analysis. In addi-
tion, nonmedical costs, such as loss of income, transportation, and caregiver
costs, are not included as they are not billed to Medicare, making our
analysis from the payer perspective.
We inﬂation adjusted cost data to 2010 US dollars using themedical care
component of the Consumer Price Index and then calculated lifetime costs
using a phase-of-care approach [28]. Monthly median costs were calculated
for the ﬁrst year after diagnosis, the middle years (year 2 after diagnosis
until the year before death), and the last year before death. For patients
living less than 2 years, the median monthly costs were calculated from
diagnosis to death.
Cost-Effectiveness
Both survival and cost were discounted 3% annually, as recommended
by the panel on cost-effectiveness analysis [29]. For patients who died
within the follow-up period, actual costs and survival were used. For pa-
tients who lived beyond the follow-up period, survival was forecasted after
the patients were censored at last follow-up by a Weibull survival model
ﬁtted to the available data and projected for full life expectancy to incor-
porate costs until death for all patients. Actual costs were used until the time
of censoring and projected from then until death using regression models.
Forecasted costs and survival were probabilistic using distributions around
the parameters in the survival model and a gamma distribution for cost. The
population was then bootstrapped 1000 times and the results averaged to
calculate ICER in cost per LY. LYs were selected rather than QALYs because
requisite utility weights for quality adjustment are not available across
phases of treatment. A cost-effectiveness acceptability curve was created to
demonstrate the probability of an Auto HSCT being cost-effective at various
willingness-to-pay thresholds.
Statistical Analysis
All statistical analyses were performed using SAS (version 9.3, SAS, Cary,
NC), Stata (version 12, StataCorp, College Station, TX) and Excel (Microsoft,
Redmond, WA).
RESULTS
Patient Demographics
Between 2000 and 2007, there were 10,832 people over
age 65 with Medicare Part A and B FFS identiﬁed as having
MM in SEER (Figure 1). From that group, the ﬁnal sample
consisted of 270 patients who underwent Auto HSCTand 270
matched patients who did not undergo transplantation.
Table 1 describes the demographic characteristics of the 2
cohorts, which did not differ signiﬁcantly as a result of our
matching (C statistic¼ .87). The median age at diagnosis was
68 (range, 66 to 92 years), with less than 10% of patients over
age 75. About two thirds of the sample had no comorbidities
by the CCI. Geographic variability was evident in our popu-
lation. The majority of transplantations were performed in
New Jersey, California, and Louisiana, with the rest of the
registries contributing smaller portions.
Figure 1. Patient selection.
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With a median follow-up of 3.5 years, the median OS
from diagnosis in the patients who underwent trans-
plantation was signiﬁcantly longer than in patients who did
not (58 months versus 37 months, log rank P < .001,
Figure 2). Survival at 1 year was 95% versus 86% (P < .001);
at 3 years, 73% versus 50% (P < .001); and at 5 years, 47%
versus 32% (P < .001).
The median time to transplantation was 250 days, with
73% of transplantations occurring within the ﬁrst year after
diagnosis. Median post-transplantation survival was 47
months. Survival at 100 days was 94%; at 1 year, 87%; at 3
years, 60%; and at 5 years, 36%. As shown in Figure 2, the
Weibull survival estimates are consistent with the empirical
survival.Table 1
Patient Characteristics
Characteristic Transplantation
n ¼ 270
Nontransplantation
n ¼ 270
Female 108 (40) 103 (38)
Race
White 238 (88) 235 (87)
Black 22 (8) 24 (9)
Age, median (range), yr 68.6 (66-92) 68.7 (66-92)
66-69 176 (65) 170 (63)
70-75 73 (27) 84 (31)
76-92 21 (8) 16 (6)
CCI*
CCI 0 170 (63) 173 (64)
CCI 1þ 100 (37) 97 (36)
SEER registryy
Connecticut 19 (7) 19 (7)
Kentucky 16 (6) 19 (7)
Louisiana 38 (14) 35 (13)
New Jersey 84 (31) 78 (29)
California 68 (25) 78 (29)
Data presented are n (%), unless otherwise indicated.
* Patients were designated as CCI 0 if they had no comorbidities and CCI
1þ if they have a score of 1 or more.
y Registries with less than 11 patients each include: Detroit, Iowa, New
Mexico, Seattle, Utah, and Georgia.Cost
Lifetime medical costs are displayed in Table 2. For pa-
tients living less than 2 years, the median monthly cost was
almost double that in patients who underwent trans-
plantation patients than in those who did not. However, only
about 13% of the patients who underwent transplantation
lived less than 2 years, compared with 33% of the non-
transplantation sample. For patients living longer than
2 years, the median monthly cost was similar between the
ﬁrst and last years of life in the transplantation population. In
contrast, in the nontransplantation population, almost
3 times as much was spent on last year of life costs compared
to immediately after diagnosis. The ongoing care or middle
year costs were comparable between both groups. The me-
dian cost of the ﬁrst 100 days after transplantation was
$60,000 (range, $37,000 to $85,000).
Cost-Effectiveness
The ICER is calculated using the mean discounted costs
and LYs, as summarized in Figure 3A. The mean overall cost
of care of a patient who underwent transplantation was
$299,554 versus $199,973 for a patient who did not, which
is an increase of $99,581. Similarly, the mean survival was
4.94 years with transplantation compared to 3.57 years
without transplantation, which was a gain of 1.37 years with
Auto HSCT. The resultant ICER is the difference in cost
divided by the difference in LY ($99,581/1.37 years gained) or
$72,852 per LY gained.
The cost-effectiveness acceptability curve (Figure 3B)
plots a society’s willingness to pay for an intervention versus
the probability the intervention will be cost-effective below
that threshold. When using the commonly accepted
threshold of $100,000 per LY gained [30], Auto HSCT for MM
patients over age 65 is cost-effective over 90% of the time.
The instrumental variables analysis was consistent with
these results. However, varying the time the non-
transplantation sample lived to at least 12 months increased
the ICER to $125,745 (nondiscounted) and $140,855 (dis-
counted) (Appendix 2).
DISCUSSION
To our knowledge, this is the ﬁrst study evaluating the
cost-effectiveness of Auto HSCT using “real world” national
claims data for MM patients over age 65 in the era of novel
agents. The ICER compares the differences in costs and
beneﬁts between 2 strategies, with the beneﬁt in this case
being LY gained by undergoing an Auto HSCT. When condi-
tioned on survival of at least 6 months after diagnosis, we
found that elderly patients undergoing transplantation sur-
vived an average of 1.37 years longer than those patient not
undergoing Auto HSCT, which translated to amedian survival
of 58 months from diagnosis and a 3-year OS from trans-
plantation of 60%. This is similar to the 3-year OS of younger
patients of approximately 65% [5,31], although these studies
were conducted before the use of novel agents. Most recently
and using a modern induction regimen, Palumbo et al.
conﬁrmed the survival beneﬁt with Auto HSCT compared
with chemotherapy in patients < 65 years with 4-year OS
from the start of consolidation of 81.6% versus 65.3% [32].
These results likely differ from ours not only because of the
patient age, but also because of the use of tandem Auto HSCT
and maintenance lenalidomide, which would have been
unlikely to be utilized during our time frame. A recent
Japanese retrospective analysis of patients ages 65 to 70
showed a 5-year OS of conventional chemotherapy and Auto
Figure 2. Overall survival. Kaplan-Meier and Weibull model simulated survival curves until death of all patients. With a transplantation, the median survival was
58 months. Without, median survival was 37 months (log-rank P < .001).
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and Auto HSCT, OS was 87% [33]. Although our 5-year sur-
vival is lower, we suspect this is related to short follow-up
time for the more recent patients who were more likely to
have received novel agents and to a greater diversity in
patients.
In terms of cost, reviews of cost for Auto HSCT by Khera
et al. [11] and Moeremans et al. [19] have estimated that the
cost of the transplantation to be between $20,000 and
$90,000. Comparisons between studies are difﬁcult as the
time frames, countries, costs included, and available treat-
ment options vary greatly. In an analysis using a large claims
database of younger patients (<66 years) with private health
insurance, Majhail et al. reported on 791 MM patients with a
median transplantation hospitalization cost of $78,000 [12].
We found the median cost of the ﬁrst 100 days after trans-
plantation to be $60,000, which is within the same range.
Few studies have put these 2 componentsdoverall cost
and survivaldtogether to evaluate the cost-effectiveness of
Auto HSCT for MM. Previous studies have compared Auto
HSCT to conventional chemotherapy of melphalan and
prednisone in younger patients [18,20,34-36], and reported
ICERs of $20,000 to $50,000 per QALY gained. Although ourTable 2
Median Monthly Cost
Transplantation Nontransplantation
Living more than 2 years n ¼ 234 n ¼ 180
First year after diagnosis* $8337 $2607
Middle years $2435 $2088
Last year $8114 $6809
Living less than 2 years n ¼ 36 n ¼ 90
Monthlyy $13,106 $6756
Total cost of care per month during each time frame. Signiﬁcant differences
were seen only in the ﬁrst year after diagnosis for patients living longer than
2 years and monthly for those living less than 2 years.
* P < .001.
y P ¼ .013.ICER is higher, the difference may be attributed to increased
cost of the induction regimens and supportive care, as the LY
gained with transplantation in all of these studies are similar
to the 1.37 LY gained in our analysis.
Van Agthoven et al. described the only cost-effectiveness
analysis alongside a phase III trial of vincristine, doxorubicin,
and dexamethasone with or without transplantation in pa-
tients younger than 65. In this study, Auto HSCT for younger
MM patients was not cost-effective, although this was
thought to be due to short follow-up at the time the analysis
was done [19,37]. Issues with these studies include the
comparison to out-of-date therapy and the lack of sensitivity
analyses to determine how likely it would be for the ICER to
be within the willingness-to-pay threshold.
More recently, Pandya et al. has published a decision
analysis evaluating the cost-effectiveness of early versus late
Auto HSCT for MM [13]. Importantly, this study used single-
institution survival data from a clinical trial on which pa-
tients had median ages of 58 (early) and 61 (delayed) and
received thalidomide- or lenalidomide-based therapy be-
tween 2000 and 2008; cost data were obtained from previ-
ous studies by Khera et al. [11] and Fullerton et al. [38].
Interestingly, our mean overall cost of care for patients who
underwent transplantation of $299,554 is similar to the costs
presented by Pandya for both the patients who underwent
early ($249,236) and delayed ($262,610) Auto HSCT.
We performed 2 sensitivity analyses to examine our key
assumptions in choosing the nontransplantation sample.
First, we used instrumental variables, which is a method-
ology that controls for both observable and unobservable
characteristics. We describe our ﬁndings fully elsewhere,
but the results were consistent with our ﬁndings here [39].
To supplement this analysis, we also explored the impact
of varying the criteria for the nontransplantation sample to
be eligible for matching. Instead of conditioning on sur-
vival to 6 months, which was our primary analysis, we
separately conditioned on survival to least 12 months to
Figure 3. (A) Discounted ICER calculation. Scatterplot of projected incre-
mental costs and life year gains for transplantation versus no transplantation
with 1000 bootstrapped simulations. Each circle represents 1 running of the
model. The average discounted total cost of care for transplantation patients
was $299,600 and, for nontransplantation patients, was $200,000. With the
transplantation, patients lived an average of 4.94 years versus 3.97 years
without the transplantation. The average ICER is the difference of cost divided
by the difference in life-years gained. In this case, $99,600/1.37 LY ¼ $72,700/
LY. (B) Incremental cost-effectiveness acceptability curve. The ICER would be
less than $100,000/life year gained more than 90% of the time.
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although overall costs were not very different, survival
difference between the transplantation and non-
transplantation groups population decreased by about 6
months (See Appendix 2). With this change in survival
beneﬁt, the ICER doubles, although it remains within the
range of many other cancer therapies [40]. It suggests that
the patients who survive for at least 12 months without
transplantation may be clinically distinct from those who
underwent transplantation earlier and, as such, may not
derive the same beneﬁt from transplantation as those who
survive at least 6 months. Clinical factors at presentation,
as well as response to therapy, may permit clinicians to
predict which patients should undergo transplantation
earlier in their disease course to derive the beneﬁts of this
modality.
We acknowledge our study’s limitations. First, given the
nature of the data we used, disease characteristics or
responsiveness to treatment could not be used in our
propensity score to create the matched cohort or address
our secondary question about the timing of trans-
plantation in the disease course. Speciﬁcally, SEER does not
collect factors, such as the plasma cell burden, cytoge-
netics, international staging system stage, or response toinduction therapy [41-43]. Further, it is possible that some
patients with smoldering myeloma were included in the
nontransplantation population, as the diagnosis code is
the same for them. However, this would bias towards
longer survival in the nontransplantation group and would
make transplantation even more cost-effective, if it were
possible to remove them.
Second, because Medicare Part D prescription coverage
did not begin until after our time frame, oral medication
costs (primarily lenalidomide and thalidomide after Food
and Drug Administration approval in 2006) are not included
in this analysis. However, we do include the cost of borte-
zomib, which was available for the majority of our time
frame. In addition, as described above, our overall cost of care
was similar to patients treated with immunomodulatory
agents. Analysis of the novel agents has shown that costs
vary based on the drugs chosen [44-46]. As available data
accumulate on the costs and beneﬁts of novel therapeutics,
analyses, such as ours, will need to be updated.
We also acknowledge that our cost analysis may not be
translatable outside the United States, given variability in
pharmaceutical costs worldwide. Finally, we identiﬁed 270
(4.4%) Auto HSCT during the time frame of our study, based
on available billing codes. This ﬁgure is lower thanwould be
expected from transplantation registry data, which show
that about 1 of 10 patients over the age of 65 undergoes an
Auto HSCT [7,47]. One possibility is that the International
Classiﬁcation of Disease 9 or Healthcare Common Procedure
Coding System code was never present in some trans-
plantation patients’ claims. However, we think that a more
likely explanation is the representativeness of trans-
plantation centers located in SEER reporting areas.
Although New Jersey and California patients make up a
good portion of our sample, large transplantation centers in
New York, Massachusetts, Texas, and Arkansas are not
included as these states are not included in the SEER
registries.
Regardless of this, the propensity score matching allows
us to make accurate comparisons to a matched sample of
nontransplantation patients. As there are only a few trans-
plantation centers in each region (Appendix 1), we attempt
to account for interinstitution variability by including SEER
region in the matching criteria. In addition, using SEER-
Medicare strengthens our analysis by capturing all of the
treatment and complications over time, which allows not
only for inclusion of all costs incurred at any location, but
also a true determination of the overall survival beneﬁt of
Auto HSCT. Furthermore, by using a national database, we
can generalize our ﬁndings to the broader elderly US
population [48].
In conclusion, for elderly patients with MM, the use of
Auto HSCT leads to survival comparable with patients under
65 years. With an incremental cost-effectiveness ratio of
$72,850/LY, which is less than the commonly accepted
willingness-to-pay threshold of $100,000, Auto HSCT is cost-
effective when compared with nontransplantation care in
the era of novel agents and should be considered for patients
over the age of 65, particularly for those identiﬁed early in
their disease course.
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